Evidence & concentration worksheet · Healing & Recovery
TB-500 10 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
TB-500 is a common, non-standardized name used for materials related to thymosin beta-4, a naturally occurring 43-amino-acid actin-binding protein studied in cell movement and tissue repair.[1] FDA's 2026 review describes TB-500 free base as a seven-amino-acid synthetic fragment but warns that multiple salts, derivatives, and even different active moieties have been sold under the same name.[15] Product identity therefore cannot be inferred from the label alone.
TB-500 is not an FDA-approved drug. Most proposed benefits are extrapolated from thymosin beta-4 research rather than direct, controlled human trials of a chemically verified TB-500 product.
Benefits & side effects
Direct TB-500 evidence is sparse. Animal wound-healing and cardiac-repair studies largely concern thymosin beta-4, not a standardized TB-500 fragment.[4][11] Registered human trials of thymosin beta-4-related investigational products involve specific formulations and indications that are not equivalent to products sold online as TB-500.[7][15]
Claims about faster tendon or ligament recovery or broadly accelerated healing therefore remain unproven extrapolations, not established human outcomes.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- UniProt — Thymosin beta-4 protein entry (2026)
- Annals of the New York Academy of Sciences — Beta-thymosins review (2007)
- Journal of Investigative Dermatology — Thymosin beta-4 in an experimental wound-healing model (1999)
- ClinicalTrials.gov — Thymosin beta-4 trial registry search (2026)
- U.S. FDA — Compounding and FDA: questions and answers (2026)
- U.S. FDA — Unapproved drugs (2026)
- WADA — The Prohibited List (2026)
- Nature — Thymosin beta-4 and cardiac cell migration and repair (2004)
- U.S. FDA — July 2026 Pharmacy Compounding Advisory Committee meeting (2026)
- U.S. FDA — FDA briefing document for TB-500-related bulk drug substances (2026)
- U.S. FDA — GenoGenix warning letter (2026)
Other vial sizes